» Articles » PMID: 28646552

Targeting Histone Deacetylase 4/ubiquitin-conjugating Enzyme 9 Impairs DNA Repair for Radiosensitization of Hepatocellular Carcinoma Cells in Mice

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2017 Jun 25
PMID 28646552
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Several strategies to improve the efficacy of radiation therapy against hepatocellular carcinoma (HCC) have been investigated. One approach is to develop radiosensitizing compounds. Because histone deacetylase 4 (HDAC4) is highly expressed in liver cancer and known to regulate oncogenesis through chromatin structure remodeling and controlling protein access to DNA, we postulated that HDAC4 inhibition might enhance radiation's effect on HCC cells. HCC cell lines (Huh7 and PLC5) and an ectopic xenograft were pretreated with HDAC inhibitor or short hairpin RNA to knock down expression of HDAC4 and then irradiated (2.5-10.0 Gy). We evaluated cell survival by a clonogenic assay; apoptosis by Annexin V immunofluorescence; γH2AX, Rad51, and HDAC4 by immunofluorescence staining; HDAC4, Rad51, and ubiquitin-conjugating enzyme 9 (Ubc9) in HCC cell nuclei by cell fractionation and confocal microscopy; physical interaction between HDAC4/Rad51/Ubc9 by immunoprecipitation; and the downstream targets of HDAC4 knockdown by immunoblotting. Both HDAC4 knockdown and HDAC inhibitor enhanced radiation-induced cell death and reduced homologous recombination repair of DNA double-strand breaks and protein kinase B activation, leading to increased apoptosis. HDAC4 knockdown with or without an HDAC inhibitor significantly delayed tumor growth in a radiation-treated xenograft model. Radiation stimulated nuclear translocation of Rad51 in an HDAC4-dependent manner and the binding of Ubc9 directly to HDAC4, which led to Ubc9 acetylation. Moreover, these effects were accompanied by HDAC4/Ubc9/Rad51 complex dissociation through inhibiting nuclear translocation. Conclusion: HDAC4 signaling blockade enhances radiation-induced lethality in HCC cells and xenografts. These findings raise the possibility that HDAC4/Ubc9/Rad51 complex in DNA repair may be a target for radiosensitization of HCC. (Hepatology 2018;67:586-599).

Citing Articles

Comprehensive Analysis of the Prognostic Implications and Biological Function of HDACs in Liver Hepatocellular Carcinoma.

Cui Z, Zheng C, You Y, He S, Jiang S, Chen Y Int J Med Sci. 2024; 21(14):2807-2823.

PMID: 39512688 PMC: 11539383. DOI: 10.7150/ijms.97169.


Nanofiber-based delivery of evodiamine impedes malignant properties of intrahepatic cholangiocarcinoma cells by targeting HDAC4 and restoring TPM1 transcription.

Zou R, Wang Y, Cai Y, Xing Z, Shao Y, Li D Hum Cell. 2024; 37(5):1505-1521.

PMID: 39073525 DOI: 10.1007/s13577-024-01105-7.


SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer.

Lachiondo-Ortega S, Rejano-Gordillo C, Simon J, Lopitz-Otsoa F, C Delgado T, Mazan-Mamczarz K Cell Rep. 2024; 43(3):113924.

PMID: 38507413 PMC: 11025316. DOI: 10.1016/j.celrep.2024.113924.


Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response.

Lee R, Sad K, Fawwal D, Spangle J Cancers (Basel). 2023; 15(15).

PMID: 37568822 PMC: 10417282. DOI: 10.3390/cancers15154005.


HDAC-an important target for improving tumor radiotherapy resistance.

Ling R, Wang J, Fang Y, Yu Y, Su Y, Sun W Front Oncol. 2023; 13:1193637.

PMID: 37503317 PMC: 10368992. DOI: 10.3389/fonc.2023.1193637.